New York, NY / June 4, 2014 / Market Exclusive announces that SummerStreet Research Partners has reiterated a BUY rating and year end 2014 price target or $15.10 on Northwest Biotherapeutics, Inc. (NWBO).
According to the SummerStreet Research report "NWBO has the potential to significantly improve the treatment of newly diagnosed GBM and other solid tumor cancers. NWBO has developed a platform technology, DCVax, that produces personalized immune therapy. NWBO has two product candidates for all solid tumors and a third product for prostate cancer."
NWBO is a biotechnology company developing immunotherapy products to treat cancers. The company has a broad platform technology with DCVax dendritic cell-based vaccines. The therapeutic vaccines utilize patients' own cells to destroy cancer cells with better specificity and less toxicity than traditional chemotherapies. The lead program is a 312- patient phase III trial in newly diagnosed GBM, the most aggressive and lethal form of brain cancer. The second product candidate is DCVax Direct, which has begun phase I/II trials at MD Anderson for all inoperable solid tumors. In addition, the FDA has approved a 612-patient phase III trial of DCVax for prostate cancer.
About Market Exclusive
Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive
- Disease & Medical Conditions
- prostate cancer